ReadCoor, Inc. Appoints Dennis Flannelly to its Board of Directors

July 6, 2020

Cambridge, Mass., July 6, 2020 – ReadCoor, Inc., a company leading true multi-omic spatial sequencing, today announced the appointment of Dennis Flannelly to its Board of Directors. Flannelly brings extensive expertise in early and late-stage product development, core in-line pharmaceutical product tactical execution, and managing medium to large-scale diagnostics businesses. He is currently the Head of Precision Medicine for US Oncology at Merck, known as MSD outside of the United States and Canada.

“We are thrilled to welcome Dennis to our Board of Directors. As a global leader in developing diagnostic businesses, he thoroughly understands the market, challenges, and opportunities in this space,” said Richard Terry, ReadCoor’s Chief Executive Officer, Chief Technology Officer, and Founder.

Flannelly has served as a leader of successful businesses in the biotech and pharma industry for over 20 years. Prior to joining Merck, Flannelly served in leadership roles at PerkinElmer, most recently as the Vice President and General Manager of the Immunodiagnostics Business, and previously as Vice President of Maternal-Fetal Health. Before PerkinElmer, Flannelly was the Global Director of Clinical Marketing at Thermo Fisher Scientific’s ImmunoDiagnostics Business. He also served as the Head of US Marketing.

“I am excited about joining ReadCoor’s Board,” stated Dennis Flannelly. “I look forward to working alongside my fellow Board members and company management regarding the world’s first true spatial sequencing platform to enhance the research potential and power applications to benefit patient care.”

Flannelly has a Bachelor of Science from Villanova University and a Master of Business Administration from Saint Joseph’s University.

About ReadCoor

ReadCoor is a technology company offering the first true spatial multi-omic platform to the global audience of researchers, clinicians, pharma and diagnostics companies to expand understanding of human biology and to facilitate the creation of new therapeutics for patients. The company’s RC2 Platform simultaneously detects and reads the sequences of tens to thousands of RNA, DNA, proteins, and therapeutics and visualizes sub-cellular nanoscale 3D resolution in every cell throughout any tissue section. The Platform, based on ReadCoor’s proprietary Fluorescent in situ Sequencing (FISSEQ) technology, combines the massive multiplexity of next-generation sequencing (NGS) and high-resolution tissue imaging. Learn more at

Media Contact
Jermaine Reid
ReadCoor, Inc.